Curriculum Vitae

Personal information

Timothy Wood

Work experience

June 2023 – Dec 2025
Managing director /CEO
Simplexia AB, Stockholm, Sweden
Responsibilities:

- Managing overall operations and setting the company's strategic direction
- Economic reporting (P&L) to financial authorities, board and shareholders
- Strategic and operational responsibility for product development, including:
- Staff management
- Development strategy
- Oversight of contractors
- Preparation of agreements
- Subject matters expertise, when required
- Communication with investors including:
- Preparation of scientific and financial business cases, including company valuations (rNPV)
- Preparation of scientific presentation material
- Identification of potential investors
- Participation in and pitch presentation at partnering meetings / conferences

June 2018 – June 2023
Vice President, CMC and Regulatory and Quality Affairs
Intervacc AB, Stockholm, Sweden
Responsibilities:

- Strategic and operative responsibility for veterinary vaccine development and pharmaceutical distribution in Nordic countries via subsidiary Nordvacc AB, including:
- External manufacturing at CDMO; technical transfer, validation and commercial scale-up
- Regulatory affairs and health authority submissions
- Quality management system for pharmaceutical marketing and distribution (Responsible person for GDP)
- Pharmacovigilance (Deputy Qualified person for pharmacovigilance, QPPV)
- Quality manager for Intervacc subsidiary Mybac Vettech, a Swedac accredited (ISO/IEC 17025) diagnostic laboratory

- Project lead for gaining marketing approval for a vaccine product via the EMA centralized procedure.
- Lead for pharmacovigilance and GDP inspections performed by the Swedish Medical Products Agency.

Oct 2015 – June 2018
Head of Regulatory Affairs
Valneva Sweden, Stockholm, Sweden
Responsibilities:

- Member of site leadership team for industrial operations, defining and reporting strategic budget and operational goals for regulatory compliance and lifecycle management
- Strategic and operational responsibility for regulatory submissions and lifecycle management (both CMC and clinical) for commercial vaccine product in:
- EU
- Canada
- Australia and New Zealand
- South East and South Asia (excl. Japan)
- South Africa
- Health authority contacts and negotiations (including US FDA)
- GMP change control approval board co-chair
- Management of outsourced regulatory activities
- Departmental budget management
- Personnel coaching / development

April 2012 – Oct 2015
Section Manager, Technical Operations
Crucell Sweden, Stockholm, Sweden
Responsibilities:

- Strategic project planning as member of steering group for manufacturing development
- Environment, health and safety for biosafety level 2 laboratory
- Personnel coaching / development
- Subject matter expert / process owner for manufacturing
- Project leader for change management activities
- Supplier inspections for raw materials
- Departmental budget management
- Interim head of QC team for contract manufacturing (1 year)

April 2011 - April 2012
Unit Manager
TFS AB, Stockholm, Sweden
Responsibilities:

- Department budget management
- Personnel coaching, development and training
- Recruitment and placement of consultants at customer sites (business development)
- Consultant regulatory affairs assignments

Jan 2010 – April 2011

Project Manager, Scientific and Regulatory Affairs

Diamyd Medical AB, Stockholm, Sweden

Responsibilities:

- Coordination of collaboration with big pharma pharmaceutical company partner
- Coordination with central trial analysis laboratory
- Report finalization and data analysis for phase II trials
- Authorship of regulatory documentation including EU orphan drug application and paediatric investigation plan

Jan 2009 – Jan 2010

Regulatory Affairs Manager

Crucell - SBL Vaccin AB, Stockholm, Sweden

Responsibilities:

- Registration of vaccine in several Asian countries
- Patient information (FASS) text updates
- Compilation and reporting of quality data to regulatory authorities
- Submission of CMC variations for cholera vaccine for EU and WHO
- Upgrade of dossier to eCTD standard
- Pharmacovigilance reporting and follow up
- Pharmacovigilance staff education for Nordic region

April 2006 – Jan 2009

Line manager / project manager, Department of Microbiology and Immunology

Crucell - SBL Vaccin AB, Stockholm, Sweden

Responsibilities:

Line manager for scientists working with development of novel vaccines and GLP / GMP analytical methods for clinical trial samples. Responsible for project management, day-to-day laboratory management, budget and personnel development.

Aug 2005 – April 2006

Regulatory Affairs Manager

Astra Zeneca R&D, Lund, Sweden

Responsibilities:

Regulatory affairs manager working with registration of asthma drug in Eastern Europe, South Africa and Asia (excluding Japan), and update of patient information text in EU.

Jan-2001 – April 2005Project Manager, Affibody AB, Bromma, Sweden

Project manager responsible for pre-clinical development, regulatory affairs, quality management and regulatory agency contacts.

Jan 1999 - Jan2001Section Manager, Pharmacia and Upjohn, Stockholm, Sweden

Line manager for Gene Analysis Group responsible for scientists working with identification of novel targets for drug discovery.

Dec 1996 – Jan 1999
Staff Scientist / post-doctoral scientist
Pharmacia and Upjohn, Stockholm, Sweden
Responsibilities:
Project manager for a discovery research project.
On post-doctoral secondment funded by Pharmacia and Upjohn for two years at:

- Royal Institute of Technology (KTH), Stockholm (supervisor Joakim Lundeberg)
- The Institute for Genomics Research, Rockville, Maryland, USA (supervisor John Quackenbush)

Education and training

March 2020 - April 2020
Industrial galenic formulation
Uppsala University, Sweden
7.5 higher education credits (5 weeks of full-time study).
Required course for EU qualified person (QP) / responsible person (RP)

Jan 1990 - Dec 1996
D. Med. Sci. (PhD)
Karolinska Institute, Stockholm, Sweden.
Graduate studies in molecualr cell biology. Thesis: Growth hormone, JAKs and STATs : a model cytokine signal transduction system

Sept 1985 - June 1989
BA Hons (Biochemistry and Chemical Pharmacology)
Hertford College, Oxford University, Oxford, UK.
Undergranduate degree in biochemistry and chemical pharmacology

Additional information

Publications

Growth Hormone Pretranslationally Regulates the Sexually Dimorphic Expression of the Prolactin Receptor Gene in Rat Liver. Robertson JR, Haldosèn L-A, Wood TJJ, Steed M and Gustafsson J-Å (1990) Mol. Endo. 4,1235-1239.

Identification of the Major Cytochrome P450s of Subfamily 2C that are Expressed in Brain of Female Rats and in Olfactory Lobes of Ethanol Treated Male Rats. Zaphiropoulos PG and Wood T. (1993) Biochem. Biophys. Res. Comm. 193, 1006-1013.

Growth Hormone Specifically Regulates Serine Protease Inhibitor Gene Transcription via a gamma-activated-like DNA Element. Sliva D*, Wood TJJ*, Schindler C, Lobie PE and Norstedt G. (*Joint first authors) (1994) J. Biol. Chem. 269, 26208-26214.

The Cellular Mechanism of Growth Hormone Signal Transduction. Lobie PE, Wood TJJ, Sliva D, Billestrup N, Waters MJ, Enberg B and Norstedt G. (1994) Acta Paed. Scand. 406, 39-48.

Cell transfection as a tool to study growth hormone action. Norstedt G, Enberg B, Francis S, Hansson A, Hulthen A, Lobie PE, Sliva D, Wood TJ, Billestrup N. (1994) Proc. Soc. Exp. Biol. Med. 206, 181-4.

Nuclear Translocation and Anchorage of the Growth Hormone Receptor. Lobie PE, Wood TJJ, Chen CM, Waters MJ and Norstedt G. (1994) J. Biol. Chem. 269, 31735-31746.

Mediation of Growth Hormone Signal Transduction by Stat 5 / Mammary Gland Factor. Wood TJJ, Sliva S, Lobie PE, Pircher T, Gouilleux F, Wakao H, Gustafsson J-Å, Groner B, Norstedt G and Haldosèn L-A. (1995) J. Biol. Chem. 270, 9448-9453.

Specificity of Transcription Enhancement via the STAT Responsive Element in the Serine Protease Inhibitor 2.1 Promoter. Wood TJJ, Sliva S, Lobie PE , Goullieux F, Mui AL, Groner B, Norstedt G and Haldosèn L-A. (1997) Mol. Cell. Endo. 130, 69-81.

Stimulation of Kinase Cascades by Growth Hormone; a Paradigm for Cytokine Signalling. Wood TJJ, Haldosén L-A, Sliva S, Sundström M and Norstedt G. (1997) Prog. Nucl. Acid Res. Mol. Biol. 57, 73-94.

Growth hormone-induced reorganization of the actin cytoskeleton is not required for STAT5 (signal transducer and activator of transcription- 5)-mediated transcription. Goh EL, Pircher TJ, Wood TJ, Norstedt G, Graichen R, Lobie PE. (1997) Endocrinology 138, 3207-15

In Vitro Interaction between STAT 5 and JAK 2; Dependence upon Phosphorylation Status of STAT 5 and JAK 2. Flores-Morales A, Pircher T, Silvenoinen O, Gustafsson J-Å, Norstedt G, Haldosèn L-A, and Wood TJJ. (1998) Mol. Cell. Endo. 138, 1-10.

A cDNA RDA Protocol Using Solid-Phase Technology Suited for Analysis in Small Tissue Samples. Odeberg J, Wood T, Blucher A, Rafter J, Norstedt G, Lundeberg J. (2000) Biomol.

Eng. 17, 1-9.

Differentially Expressed Transcripts in Neoplastic Nodules and Neonatal Rat Liver Studied by cDNA Microarray Analysis. Tellgren Å, Wood TJJ, Flores-Morales A, Torndal U-B, Eriksson L, Norstedt G. (2003) Int. J. Cancer 104(2), 131-138.

Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Ludvigsson J, Hjorth M, Chéramy M, Axelsson S, Pihl M, Forsander G, Nilsson N-O, Samuelsson B-O, Wood T, Åman J, Örtqvist E, Casas, R. (2011) Diabetologia. 54(3), 634-40.

Sow vaccination with a novel recombinant protein vaccine protects piglets against Streptococcus suis infection. Frosth S, Reddick D, Righetti F, Bjerketorp J, Jacobsson K, Henriques-Normark B, Jacobson M, Guss B, Wood T, Frykberg L, Flock JI, Waller A. (2025) Vaccine. 2025 53:127077.

Neutralisation of the immunoglobulin-cleaving activity of Streptococcus equi subspecies equi IdeE by blood sera from ponies vaccinated with a multicomponent protein vaccine. Francesco Righetti, Karina Hentrich, Margareta Flock, Sara Frosth, Karin Jacobsson, Joakim Bjerketorp, Anuj Pathak, Noela Ido, Birgitta Henriques-Normark, Lars Frykberg, Romain Paillot, Bengt Guss, Tim Wood, Jan-Ingmar Flock, Andrew Stephen Waller (2025) Vaccines 2025, 13(10), 1061

Projects

Research and development for human vaccine against genital herpes caused by herpes simplex virus 2. Coordinator for EU Eurostars project for human vaccine against herpes simplex virus 2.

Development and EMA regulatory approval of veterinary vaccine against strangles caused by *Streptococcus equi.*

Project member in EU Eurostars project for veterinary vaccine against *Streptococcus suis.*

Manufacturing of human vaccine against cholera.

Research and development for human vaccine against Enterotoxigenic *Escherichia coli* (ETEC).

Memberships

Other Relevant Information